FY2019 EPS Estimates for AbbVie Inc Raised by Leerink Swann (ABBV)
AbbVie Inc (NYSE:ABBV) – Investment analysts at Leerink Swann increased their FY2019 earnings per share estimates for AbbVie in a report released on Thursday. Leerink Swann analyst G. Porges now expects that the company will earn $9.37 per share for the year, up from their previous estimate of $8.36. Leerink Swann currently has a “Buy” rating and a $106.00 target price on the stock.
Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Monday. Argus lifted their price objective on shares of AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a report on Friday, September 29th. UBS Group lowered shares of AbbVie from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $79.00 to $92.00 in a report on Monday, September 25th. Jefferies Group reaffirmed a “buy” rating and issued a $107.00 price target on shares of AbbVie in a report on Thursday, September 28th. Finally, Barclays reaffirmed a “hold” rating and issued a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $101.38.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company posted $1.21 earnings per share.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.68%. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is currently 68.93%.
In other news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock worth $47,237,938 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.
Large investors have recently bought and sold shares of the company. Cornerstone Investment Partners LLC lifted its position in AbbVie by 100.0% during the fourth quarter. Cornerstone Investment Partners LLC now owns 31,470 shares of the company’s stock valued at $3,043,000 after purchasing an additional 15,735 shares during the period. Steward Partners Investment Advisory LLC lifted its position in AbbVie by 2.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 66,316 shares of the company’s stock valued at $6,413,000 after purchasing an additional 1,561 shares during the period. Round Table Services LLC acquired a new position in AbbVie during the fourth quarter valued at $207,000. V Wealth Management LLC lifted its position in AbbVie by 24.3% during the fourth quarter. V Wealth Management LLC now owns 3,892 shares of the company’s stock valued at $399,000 after purchasing an additional 762 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in AbbVie during the fourth quarter valued at $399,000. Institutional investors and hedge funds own 69.22% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.